Gene-Editing Clinical Trials for Beta Thalassemia
Feb. 2, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories
Main focus: Gene editing of haematopoietic stem cells and next generation CAR-T cells
Company stage: Clinical
Diseases: Beta-thalassemia, alpha-thalassemia, multiple haematological and solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Shanghai, China
Website: https://www.bioraylab.com/
Bioray Laboratories is a Shanghai-based company focusing on the development of haematopoietic stem cell (HSCs)-based medicines as well as next generation CAR-T cell-based therapies. The company uses CRISPR to knock out various targets within the genomes of HSCs and CAR-T cells. Currently, the company is conducting multiple clinical trials in which CRISPR-Cas9 is being used for the treatment of beta-thalassemia and B-cell lymphomas using CAR-T.
Tags
Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories
